NovaBridge Biosciences
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $231.3M
- Price
- $2.00
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.71%
- Volume
- 443.1K
About
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Quick stats
Shares outstanding115.6M
Computed float42.0M
Float / shares36.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001778016
Websitehttps://www.novabridge.com
AI Summary
AI-generated1/11
standardbullishearnings
NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution
NovaBridge reported a cash position of $215.9 million as of June 30, 2026, providing sufficient runway to fund operations through key milestones including givastomig's Phase 3 interim data read-out in 2028.
The company highlighted strategic progress with the appointment of Srishti Gupta as CEO and the receipt of FDA Fast Track Designation for givastomig in first-line metastatic gastric cancer.
Pipeline updates indicate Phase 3 initiation for givastomig is planned for year-end 2026, while the ophthalmology asset VIS-101 is set to enter Phase 2b in the second half of 2026.
Red flags
- Net loss widened to $37.9 million from $8.7 million in the prior-year period
- Administrative expenses increased significantly to $26.4 million, driven by share-based compensation and a one-time write-off